Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Aardvark Therapeutics, Inc. (AARD) had Consolidated Net Income/Loss of $-21.59M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-21.59M |
|
-- |
|
-- |
|
$22.46M |
|
$-22.46M |
|
$0.88M |
|
$-21.59M |
|
$-21.57M |
|
$-21.59M |
|
$-21.59M |
|
|
Consolidated Net Income/Loss |
$-21.59M |
$-21.57M |
|
$-22.46M |
|
$-22.57M |
|
21.82M |
|
21.82M |
|
$-0.99 |
|
$-0.99 |
|
| Balance Sheet Financials | |
$93.58M |
|
-- |
|
$5.01M |
|
$98.59M |
|
$11.60M |
|
-- |
|
-- |
|
$11.60M |
|
$86.99M |
|
$86.99M |
|
$86.99M |
|
21.82M |
|
| Cash Flow Statement Financials | |
$-18.87M |
|
$34.25M |
|
$0.00M |
|
$47.05M |
|
$62.44M |
|
$15.38M |
|
$2.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.87M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.82% |
|
-24.82% |
|
-21.90% |
|
-24.82% |
|
$3.99 |
|
$-0.86 |
|
$-0.86 |
|